Management of Bleeding Gastric Ulcer

Confirmation of H. pylori Status

In a bleeding gastric ulcer with a negative biopsy for H. pylori, the test for H. pylori should be repeated outside of the acute bleeding context due to high rates of false negatives during active bleeding, and treatment with high-dose proton pump inhibitors (PPIs) should be initiated for 6-8 weeks, while suspending nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin if present, and a follow-up endoscopy should be performed at 6 weeks to confirm healing and exclude malignancy, as recommended by the American College of Gastroenterology 1, 2, 3
Tests for H. pylori have increased rates of false negatives in the context of acute bleeding, so an initial negative result does not definitively rule out infection, according to the American Gastroenterological Association 1, 2, 3
A confirmatory test should be performed outside of the acute bleeding context if the initial test was negative during the bleeding episode, as suggested by the American College of Gastroenterology 1, 2, 3

High-dose PPIs should be administered: a bolus of 80mg followed by a continuous infusion of 8mg/hour for 72 hours after endoscopic hemostasis in high-risk ulcers, as recommended by the European Society of Gastrointestinal Endoscopy 4
PPIs should be continued orally for 6-8 weeks after endoscopic treatment to allow mucosal healing, regardless of H. pylori status, according to the World Gastroenterology Organisation 5, 6, 4
PPI therapy should be continued until complete healing of the gastric ulcer is confirmed on follow-up endoscopy, as suggested by the British Society of Gastroenterology 7, 8

All NSAIDs and aspirin should be immediately suspended if present, as recommended by the American Heart Association 9, 10, 11
If a patient requires continued NSAIDs for valid medical reasons, the least harmful agent (ibuprofen) should be used in combination with PPIs, according to the European Society of Cardiology 9, 10, 11

A follow-up endoscopy should be performed approximately 6 weeks after hospital discharge to confirm ulcer healing and exclude malignancy, as recommended by the American Society for Gastrointestinal Endoscopy 9, 10, 11
This follow-up endoscopy is mandatory in gastric ulcers (unlike duodenal ulcers) due to the risk of underlying malignancy, according to the National Comprehensive Cancer Network 9, 10, 11

The International Consensus Group provides a strong recommendation (moderate-quality evidence) for initiating intravenous PPI regimen with an 80mg bolus of omeprazole (or equivalent PPI) immediately after successful endoscopic therapy, followed by continuous infusion at 8mg/hour for 72 hours, in patients with high-risk stigmata who underwent successful endoscopic therapy 12, 13
Pre-endoscopic PPI administration may reduce the need for endoscopic therapy but does not improve mortality, rebleeding, or surgical outcomes, so it should not delay urgent endoscopy 13

The American College of Physicians recommends switching to oral PPI 40mg twice daily for the next 11 days (completing 14 days total of high-dose therapy) after completing the 72-hour infusion 12
The World Society of Emergency Surgery recommends continuing oral PPI therapy for a total duration of 6-8 weeks to allow complete mucosal healing, specifically for peptic ulcer bleeding after endoscopic treatment 13, 14
The European Society of Gastrointestinal Endoscopy recommends reducing to 40mg once daily after the initial 14 days and continuing for a total duration of 6-8 weeks 14

The American College of Gastroenterology recommends testing all patients for H. pylori infection and providing eradication therapy if confirmed positive, with documentation of cure 12, 13
The International Consensus Group recommends immediately discontinuing all NSAIDs and aspirin during the acute bleeding episode, and using the least harmful agent (ibuprofen) combined with a PPI if NSAIDs must be resumed for valid medical reasons 14
The American Heart Association recommends restarting aspirin within 1-7 days (ideally 1-3 days) once hemostasis is achieved, along with PPI therapy, for patients requiring cardiovascular prophylaxis with aspirin 12

The American College of Gastroenterology recommends discontinuing PPI after documented H. pylori eradication, as rebleeding becomes extremely rare 14
The European Society of Gastrointestinal Endoscopy recommends maintaining indefinite PPI therapy with COX-2 inhibitor for NSAID-associated ulcers, and continuing indefinite PPI therapy for aspirin users with cardiovascular disease 12